Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?

Executive Summary

The Vioxx labeling change will allow Merck to discuss the COX-2 inhibitor's cardiovascular safety profile in the context of a rheumatoid arthritis indication and a gastrointestinal safety benefit

You may also be interested in...



Merck’s Vioxx Conduct Receives Passing Grade In Review By Outside Firm

An independent report contracted by Merck has concluded that the company's senior executives did not mishandle the development, testing and marketing of Vioxx (rofecoxib), despite the fact that the product is widely viewed as one of the more significant debacles in pharmaceutical history

Merck’s Vioxx Conduct Receives Passing Grade In Review By Outside Firm

An independent report contracted by Merck has concluded that the company's senior executives did not mishandle the development, testing and marketing of Vioxx (rofecoxib), despite the fact that the product is widely viewed as one of the more significant debacles in pharmaceutical history

Merck Will Need VIGOR To Defend Vioxx Data Following NEJM Claims

The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication

Related Content

UsernamePublicRestriction

Register

PS039683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel